EN DE
Watch Autolus Therapeutics Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Autolus Therapeutics Ltd (AUTL) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Autolus Therapeutics Ltd stock $1.07, price $1.32, that is 18.9% below the price, quality 35 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in United Kingdom

AT Autolus Therapeutics Ltd logo Thin data Nov 10, 2026

Autolus Therapeutics Ltd

AUTL · US
Expensive, weak quality

Our calculation puts a fair price 19% below what the stock costs today.

Revenue last quarter +118% vs. a year ago.
Mixed Growth (revenue 5y +113.2 %/yr in USD)
Mixed vs. peers (4/8)
Insiders sold $15,708 (6M)
Fair value $1.07 · Overvalued
Quality 35/100
Negative free cash flow
Narrow moat 9/100
Negative coverage
Thin data
Estimate
Watch Autolus Therapeutics Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$7.37 $1.14 Fair Value $1.07 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $1.14 – $7.37 · fair‑value band $0.8000 – $1.34 · the $1.32 price screens above the $1.07 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Autolus Therapeutics in your weekly email

Every Wednesday you see whether Autolus Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.

Show moreShow less

The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.

It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia.

The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Stock analysis

Autolus Therapeutics Ltd (AUTL) currently trades at $1.32, while our estimate is $1.07, 19% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.8000 (bear) to $1.34 (bull), the price of $1.32 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Autolus Therapeutics Ltd reported revenue of $75.6M in FY2025 versus $1.5M in FY2021, a compound +166.1%/yr. Reported net income was −$288M in FY2025.

Key figures

Market cap $351M Small · P/S ratio 2.90 · EPS (TTM) $−1.06 · Return on equity −133% · Return on assets (EBIT) −38.1% (5-year average) · Operating margin −96.0% · Revenue (TTM) $117M · Revenue growth (YoY) +118%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 48% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −19%, AUTL screens richer than that median.

Fair Value

Bear $0.8000 Fair Value $1.07 Bull $1.34
Price $1.32 · Downside -18.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 80
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 49
Debt, balance sheet and risk of trouble
Investment 56
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 26
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 20
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $15,708 and none bought.

  • SaleCintia PiccinaU.S. CCO & Country Gen Manager6,713 shares at $2.34$15,708Sep 2, 2026

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+646.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+130.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+113.2%
Start year 2020 (pandemic). Over 10 years: +95.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+95.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−17,675.4% (2020) → −372.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

AUTL screens overvalued: fair value 19% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (93 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Negative
Recent news coverage is more negative than average.

Compare Autolus Therapeutics Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside −18.9% · Above median
Profitability
Return on assets −48.9% · Bottom 25%
Operating margin (12 months) −96.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 118.4% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.97× · Cheaper than median
P/S (12 months) 2.99× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)8 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs AUTL
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs AUTL
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs AUTL
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs AUTL
argenx SE ARGX $971.55 $908.40 −7% vs AUTL
CSL Limited CSL A$201.68 A$181.40 −10% vs AUTL
Moderna, Inc MRNA $250.83 $158.70 −37% vs AUTL
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs AUTL
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs AUTL
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs AUTL

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Autolus Therapeutics Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Autolus Therapeutics Ltd Fair Value". https://www.fairvalue-calculator.com/stock/AUTL

Frequently asked questions

Is Autolus Therapeutics Ltd (AUTL) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $1.07 versus a price of $1.32, about 19% lower (overvalued).
What is the fair value of AUTL?
Our estimate for Autolus Therapeutics Ltd is $1.07 (as of Nov 10, 2026), built from audited fundamentals. The current price: $1.32.
What is the quality score of AUTL?
Autolus Therapeutics Ltd has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Autolus Therapeutics Ltd (AUTL)?
Our calculated price target is the estimate of $1.07 (as of Nov 10, 2026). Cautious scenario $0.8000, optimistic scenario $1.34. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Autolus Therapeutics Ltd stock forecast for 2026?
Our estimate puts fair value at $1.07, about 19% lower versus a price of $1.32 (overvalued). Cautious scenario $0.8000, optimistic scenario $1.34. The calculation is refreshed regularly with new filings.
What is the revenue of Autolus Therapeutics Ltd (AUTL)?
Autolus Therapeutics Ltd reported trailing-twelve-month revenue of about $117M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Autolus Therapeutics Ltd (AUTL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Autolus Therapeutics Ltd it is $1.07 per share (as of Nov 10, 2026), against a price of $1.32.
Is Autolus Therapeutics Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, AUTL trades above its calculated fair value: price $1.32, fair value $1.07, a gap of about −19% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AUTL?
No. The price is what the market pays today ($1.32); the fair value is what the company's own numbers justify ($1.07). For Autolus Therapeutics Ltd the two are $0.2500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Autolus Therapeutics Ltd worth?
The market values Autolus Therapeutics Ltd at about $351M (market capitalisation, as of Nov 10, 2026). Per share that is $1.32; our models calculate a fair value of $1.07 per share.
What do the bullish and bearish scenarios say about AUTL?
Our models span a range for Autolus Therapeutics Ltd: cautious scenario $0.8000, base $1.07, optimistic $1.34 per share (as of Nov 10, 2026, price $1.32). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Autolus Therapeutics Ltd (AUTL)?
Balance-sheet figures for Autolus Therapeutics Ltd (as of Nov 10, 2026): return on equity −133.0%. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is AUTL from its 52-week high?
Autolus Therapeutics Ltd trades at $1.32, about 48% below its 52-week high of $2.54 and 9% above the low of $1.21 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $1.07 is for.
Which stocks are comparable to Autolus Therapeutics Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Autolus Therapeutics Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price $1.32, calculated fair value $1.07 (−19%), Quality Score 35/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Autolus Therapeutics Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Autolus Therapeutics Ltd (AUTL)?
The closing price on Nov 10, 2026 was $1.32. Our estimate is $1.07, about 19% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Autolus Therapeutics Ltd right now?
Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Autolus Therapeutics Ltd

How large is the market capitalisation of Autolus Therapeutics Ltd (AUTL)?
The market capitalisation of Autolus Therapeutics Ltd is $351M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Autolus Therapeutics Ltd (AUTL)?
The price-to-sales ratio of Autolus Therapeutics Ltd is 2.90 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Autolus Therapeutics Ltd (AUTL)?
Earnings per share at Autolus Therapeutics Ltd are $−1.06. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Autolus Therapeutics Ltd (AUTL)?
The return on equity (ROE) of Autolus Therapeutics Ltd is −133% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Autolus Therapeutics Ltd (AUTL)?
On an EBIT basis the return on assets of Autolus Therapeutics Ltd is −38.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Autolus Therapeutics Ltd (AUTL)?
The operating margin of Autolus Therapeutics Ltd is −96.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Autolus Therapeutics Ltd (AUTL)?
Revenue at Autolus Therapeutics Ltd is growing +118% versus a year earlier (3y avg +130%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Autolus Therapeutics Ltd (AUTL) generate?
The free cash flow of Autolus Therapeutics Ltd is −$311M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Autolus Therapeutics Ltd (AUTL) carry?
The net debt of Autolus Therapeutics Ltd is $247M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Autolus Therapeutics Ltd in the live analysis

One click puts Autolus Therapeutics Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.